Nanotamoxifen delivery system: Toxicity assessment after oral administration and biodistribution study after intravenous delivery of radiolabeled nanotamoxifen
Tamoxifen is the most prescribed anticancer oral drug for increasing overall survival and decreasing recurrence and the risk of contralateral disease. However, some side effects, such as endometrial and liver tumors, thromboembolic disorders, and drug resistance, are associated with long-term tamoxi...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2016-01-01
|
| Series: | World Journal of Nuclear Medicine |
| Subjects: | |
| Online Access: | http://www.thieme-connect.de/DOI/DOI?10.4103/1450-1147.167594 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850045308299378688 |
|---|---|
| author | Jaya Shukla Amit Dinda Abhay Srivastava Kamna Srivastava Bhagwant Mittal Guru Bandopadhyaya |
| author_facet | Jaya Shukla Amit Dinda Abhay Srivastava Kamna Srivastava Bhagwant Mittal Guru Bandopadhyaya |
| author_sort | Jaya Shukla |
| collection | DOAJ |
| description | Tamoxifen is the most prescribed anticancer oral drug for increasing overall survival and decreasing recurrence and the risk of contralateral disease. However, some side effects, such as endometrial and liver tumors, thromboembolic disorders, and drug resistance, are associated with long-term tamoxifen treatment. We assessed the hematologic and organ toxicity after oral administration of three different doses of nanotamoxifen formulations. We also performed biodistribution studies of Technetium-99m (99mTc)-nanotamoxifen after intravenous administration. The results demonstrated that nanotamoxifen was well-tolerated, with no adverse effect on biochemical parameters of blood and at the cellular level. Nitric oxide (NO) levels indicated no free radical formation. Oral nanotamoxifen is well-tolerated, with no hepatic or renal toxicity. Intravenous nanotamoxifen has potential to escape the liver, and is known for producing the harmful metabolite 4-hydroxytamoxifen (4OH-tamoxifen), which can cause uterine cancer. |
| format | Article |
| id | doaj-art-c8f9d0db6ee34d8f96ff30b1f62c6e16 |
| institution | DOAJ |
| issn | 1450-1147 1607-3312 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Thieme Medical and Scientific Publishers Pvt. Ltd. |
| record_format | Article |
| series | World Journal of Nuclear Medicine |
| spelling | doaj-art-c8f9d0db6ee34d8f96ff30b1f62c6e162025-08-20T02:54:43ZengThieme Medical and Scientific Publishers Pvt. Ltd.World Journal of Nuclear Medicine1450-11471607-33122016-01-01150171110.4103/1450-1147.167594Nanotamoxifen delivery system: Toxicity assessment after oral administration and biodistribution study after intravenous delivery of radiolabeled nanotamoxifenJaya Shukla0Amit Dinda1Abhay Srivastava2Kamna Srivastava3Bhagwant Mittal4Guru Bandopadhyaya5Department of Nuclear Medicine and PET, Post Graduate Institute of Medical Education and Research, Chandigarh, IndiaDepartment of Pathology, AllInstitute of Medical Sciences, New Delhi, IndiaDepartment of Lab Medicine AllInstitute of Medical Sciences, New Delhi, IndiaDepartment of Molecular Cardiology, Dr. BR Ambedkar Center for Biomedical Research, University of Delhi, Delhi, IndiaDepartment of Nuclear Medicine and PET, Post Graduate Institute of Medical Education and Research, Chandigarh, IndiaDepartment of Nuclear Medicine and PET, All Institute of Medical Sciences, New Delhi, IndiaTamoxifen is the most prescribed anticancer oral drug for increasing overall survival and decreasing recurrence and the risk of contralateral disease. However, some side effects, such as endometrial and liver tumors, thromboembolic disorders, and drug resistance, are associated with long-term tamoxifen treatment. We assessed the hematologic and organ toxicity after oral administration of three different doses of nanotamoxifen formulations. We also performed biodistribution studies of Technetium-99m (99mTc)-nanotamoxifen after intravenous administration. The results demonstrated that nanotamoxifen was well-tolerated, with no adverse effect on biochemical parameters of blood and at the cellular level. Nitric oxide (NO) levels indicated no free radical formation. Oral nanotamoxifen is well-tolerated, with no hepatic or renal toxicity. Intravenous nanotamoxifen has potential to escape the liver, and is known for producing the harmful metabolite 4-hydroxytamoxifen (4OH-tamoxifen), which can cause uterine cancer.http://www.thieme-connect.de/DOI/DOI?10.4103/1450-1147.167594biodistributiondelivery systemfree radical formationnanotamoxifenoral doseradiolabelingtoxicity |
| spellingShingle | Jaya Shukla Amit Dinda Abhay Srivastava Kamna Srivastava Bhagwant Mittal Guru Bandopadhyaya Nanotamoxifen delivery system: Toxicity assessment after oral administration and biodistribution study after intravenous delivery of radiolabeled nanotamoxifen World Journal of Nuclear Medicine biodistribution delivery system free radical formation nanotamoxifen oral dose radiolabeling toxicity |
| title | Nanotamoxifen delivery system: Toxicity assessment after oral administration and biodistribution study after intravenous delivery of radiolabeled nanotamoxifen |
| title_full | Nanotamoxifen delivery system: Toxicity assessment after oral administration and biodistribution study after intravenous delivery of radiolabeled nanotamoxifen |
| title_fullStr | Nanotamoxifen delivery system: Toxicity assessment after oral administration and biodistribution study after intravenous delivery of radiolabeled nanotamoxifen |
| title_full_unstemmed | Nanotamoxifen delivery system: Toxicity assessment after oral administration and biodistribution study after intravenous delivery of radiolabeled nanotamoxifen |
| title_short | Nanotamoxifen delivery system: Toxicity assessment after oral administration and biodistribution study after intravenous delivery of radiolabeled nanotamoxifen |
| title_sort | nanotamoxifen delivery system toxicity assessment after oral administration and biodistribution study after intravenous delivery of radiolabeled nanotamoxifen |
| topic | biodistribution delivery system free radical formation nanotamoxifen oral dose radiolabeling toxicity |
| url | http://www.thieme-connect.de/DOI/DOI?10.4103/1450-1147.167594 |
| work_keys_str_mv | AT jayashukla nanotamoxifendeliverysystemtoxicityassessmentafteroraladministrationandbiodistributionstudyafterintravenousdeliveryofradiolabelednanotamoxifen AT amitdinda nanotamoxifendeliverysystemtoxicityassessmentafteroraladministrationandbiodistributionstudyafterintravenousdeliveryofradiolabelednanotamoxifen AT abhaysrivastava nanotamoxifendeliverysystemtoxicityassessmentafteroraladministrationandbiodistributionstudyafterintravenousdeliveryofradiolabelednanotamoxifen AT kamnasrivastava nanotamoxifendeliverysystemtoxicityassessmentafteroraladministrationandbiodistributionstudyafterintravenousdeliveryofradiolabelednanotamoxifen AT bhagwantmittal nanotamoxifendeliverysystemtoxicityassessmentafteroraladministrationandbiodistributionstudyafterintravenousdeliveryofradiolabelednanotamoxifen AT gurubandopadhyaya nanotamoxifendeliverysystemtoxicityassessmentafteroraladministrationandbiodistributionstudyafterintravenousdeliveryofradiolabelednanotamoxifen |